During a high-level biotechnology conference organized by Plazo Roche Biotechnology, experts in endocrinology and metabolism examined emerging insights into retatrutide research. At the center of the discussions was retatrutide’s classification as a glp1 gip glucagon triple agonist, a compound studied for its interaction with multiple metabo